Pharmacokinetics Of Alprazolam Sublingual Tablet Versus Conventional Tablet

• Status: Completed
• Trial end date: 2011-05-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess if the sublingual tablet will have similar pharmacokinetics as the conventional tablet of alprazolam.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Pfizer; Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
• Treatments: Alprazolam

Criteria

Inclusion Criteria:

• Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive.

• Body Mass Index (BMI) of 17.5 to 30.5 kg/m2.

• Signed informed consent.

Exclusion Criteria:

• Evidence or history of clinically significant abnormalities

• Positive drug screen, excessive alcohol and tobacco use